Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Phase 2 Data to Sink Your Teeth Into

Just in time for Thanksgiving, Novo Nordisk (NYSE: NVO  ) released phase 2 clinical trial data from its weight-loss/diabetes drug, liraglutide. It appears that investors ate it up, given the 4% bump in stock price yesterday.

The announcement was light on data, but provided evidence that liraglutide was more effective at removing the pounds than orlistat, which is marketed by Roche under the name Xenical and over the counter by GlaxoSmithKline (NYSE: GSK  ) under the name Alli.

As was the case with Amylin Pharmaceuticals' (Nasdaq: AMLN  ) phase 2 data from its weight-loss combination product released last week, it's hard to draw strong conclusions from a short trial. It's going to take a longer phase 3 trial to get data that's strong enough not only to get FDA approval, but also to persuade patients to use it instead of oral weight loss compounds like Alli and Abbott's (NYSE: ABT  ) MERIDIA.

Fortunately, Novo isn't counting on the weight-loss data to get liraglutide on the market. It's already completed four of the five planned phase 3 trials to get the drug approved for treating patients with type 2 diabetes. If data from the final trial, which will compare liraglutide to sanofi-aventis' (NYSE: SNY  ) Amaryl, show results that are similar to previous studies, Novo expects to file a marketing application in the middle of next year.

Once on the market, it would compete against Amylin's BYETTA. Liraglutide should have a competitive advantage, since it's injected once a day versus BYETTA's twice-daily regimen. But Amylin's extended-release version of BYETTA should be on its heels a year later. It looks like the diabetes market is about to get tighter than jeans on a supermodel.

Further weighty Foolishness:

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 540614, ~/Articles/ArticleHandler.aspx, 10/25/2016 12:07:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,178.56 -44.47 -0.24%
S&P 500 2,145.06 -6.27 -0.29%
NASD 5,288.09 -21.74 -0.41%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 11:51 AM
NVO $40.39 Down -0.42 -1.03%
Novo Nordisk CAPS Rating: *****
ABT $40.33 Down -0.08 -0.20%
Abbott Laboratorie… CAPS Rating: *****
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
GSK $40.34 Down -0.34 -0.84%
GlaxoSmithKline CAPS Rating: ***
SNY $37.37 Down -0.39 -1.02%
Sanofi CAPS Rating: *****